Infectious Hazard Management, Department of Health Emergency World Health Organization, Eastern Mediterranean Regional Office Cairo Egypt.
Influenza Other Respir Viruses. 2023 Nov;17(11):e13217. doi: 10.1111/irv.13217.
The COVID-19 pandemic placed unprecedented stress on laboratories in the Eastern Mediterranean Region. Building on existing capacity for influenza diagnostics, countries introduced COVID-19 diagnostic support to ~100% regional coverage. A key challenge during the expansion was maintaining quality testing in laboratories, ensuring that correct results were shared with medical facilities.
WHO organized two rounds of independently monitored severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) external quality assurance programs (EQAP). The Public Health Laboratory (PHL) division of WHO supplied external quality assurance (EQA) panels, from the Royal College of Pathologists of Australasia Quality Assurance Programme (RCPAQAP) Australia to laboratories not enrolled in recurring Global Influenza Surveillance and Response System (GISRS) quality assurance programs, in which national influenza centers routinely participate.
Fifteen and 14 countries participated in PHL/EQAP for SARS-CoV-2 between 2020 and 2022. Concordance was consistent between rounds, reaching 96.4% and 89.9%. A separate assessment of GISRS/EQAP to national-level laboratories identified high levels of response and concordance for SARS-CoV-2 (100% response, 93% concordance), which was reduced for influenza (50% response rate, 80% concordance), reflecting the challenge of prioritizing pathogens during outbreaks.
The proliferation of laboratories in response to COVID-19 was a success story from the pandemic. However, monitoring the quality of laboratories was challenging via existing EQAP. The addition of PHL/EQAP provided a mechanism to monitor performance of laboratories that were not designated as national influenza centers. While a high proportion of laboratories attained good results, continual emphasis on quality and enrollment in EQAP is key to ensuring sustainability of laboratory testing in future.
COVID-19 大流行给东地中海区域的实验室带来了前所未有的压力。各国在流感诊断方面的现有能力基础上,引入了 COVID-19 诊断支持,以实现区域覆盖率达到 100%。在扩展过程中,一个关键挑战是保持实验室的质量检测,确保将正确的结果与医疗机构共享。
世卫组织组织了两轮独立监测的严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)外部质量保证计划(EQAP)。世卫组织公共卫生实验室(PHL)司从澳大利亚皇家病理学家学院质量保证计划(RCPAQAP)向未参加全球流感监测和应对系统(GISRS)质量保证计划的实验室提供外部质量保证(EQA)检测板,国家流感中心通常参加该计划。
2020 年至 2022 年期间,15 个国家和 14 个国家的 PHL/EQAP 参与了 SARS-CoV-2 的检测。两轮检测的一致性均较高,达到 96.4%和 89.9%。对国家一级实验室进行的单独 GISRS/EQAP 评估显示,SARS-CoV-2 的反应和一致性水平较高(100%的反应率,93%的一致性),但流感的反应率较低(50%,80%的一致性),这反映了在疫情期间优先考虑病原体的挑战。
应对 COVID-19 而激增的实验室是大流行期间的一个成功案例。然而,通过现有的 EQAP 监测实验室的质量具有挑战性。PHL/EQAP 的增加提供了一种监测未被指定为国家流感中心的实验室绩效的机制。虽然很大比例的实验室取得了良好的结果,但持续强调质量和参与 EQAP 是确保未来实验室检测可持续性的关键。